Guiomar Moral‐Villarejo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guiomar Moral‐Villarejo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jacobo Ortiz-Fernandez-Sordo
Nottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre Nottingham UK
2 shared publications - Anjan Dhar
County Durham & Darlington NHS Foundation Trust Darlington UK
1 shared publication - Ashraf Sanduka
Cyted Ltd Cambridge Cambridgeshire UK
1 shared publication Ayesha Rai
East and North Hertfordshire Teaching NHS Trust Stevenage Herts UK
1 shared publication- Danielle L. Morris
East and North Hertfordshire Teaching NHS Trust Stevenage Herts UK
1 shared publication Erzsebet Santa
East and North Hertfordshire Teaching NHS Trust Stevenage Herts UK
1 shared publication
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Clinical Trial: Capsule Sponge as a Non‐Endoscopic Monitoring Tool in Eosinophilic Oesophagitis—A Prospective Real–World Multicentre Study
Background and Aims: Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition requiring repeat endoscopy and biopsy for histological monitoring, which is invasive, resource‐intensive and burdensome for patients. The capsule sponge (CS) offers a potential non‐invasive alternative. We evaluated the diagnostic accuracy, feasibility and patient acceptability of CS versus endoscopic biopsies for monitoring disease activity in adult patients. Methods: A real‐world prospective multicentre cohort study was conducted across three NHS sites in England from August 2023 to June 2025. Adults with established EoE without oesophageal strictures underwent same‐day endoscopy and CS using the Endosign device. Histological activity was defined as ≥ 15 eosinophils per high‐power field or 0.3 mm 2 on endoscopic biopsy histology and CS respectively. Symptom burden was assessed using the Dysphagia Symptom Questionnaire, endoscopic severity using the EoE Endoscopic Reference Score and patient acceptability via structured questionnaire. Results: 136 patients (164 paired episodes) from three secondary care hospitals successfully swallowed CS with sufficient sampling; CS swallowing success rate was 92.7%. Median age was 45 years (IQR 34.8–56); 92/136 (67.6%) were male. CS demonstrated sensitivity 76.3%, specificity 89.5%, PPV 80.4%, NPV 87.0% and overall accuracy 84.8% (Cohen's κ = 0.67). AUC was 0.904 (95% CI 0.856–0.953). Patient acceptability recorded 96.7% found CS acceptable, 78.8% preferred it over endoscopy, and 90.8% would repeat the procedure. No complications occurred. Conclusions: CS is a safe, feasible, accurate and highly acceptable less‐invasive tool for monitoring EoE. Its implementation could improve care pathways, reducing the need for repeated endoscopic biopsies while maintaining diagnostic reliability, with potential to reduce service burden, carbon emissions and improve patient experience. Trial Registration: CoSiE: IRAS number: 314770; ClinicalTrials.gov identifier: NCT06501274; QuBiE: UK Clinical Trial registry identifier: ISRCTN14071734; Trial number: 10083253
- 3 November 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessClinical Trial: Capsule Sponge as a Non‐Endoscopic Monitoring Tool in Eosinophilic Oesophagitis—A Prospective Real–World Multicentre Study
Background and Aims: Eosinophilic oesophagitis (EoE) is a chronic inflammatory condition requiring repeat endoscopy and biopsy for histological monitoring, which is invasive, resource‐intensive and burdensome for patients. The capsule sponge (CS) offers a potential non‐invasive alternative. We evaluated the diagnostic accuracy, feasibility and patient acceptability of CS versus endoscopic biopsies for monitoring disease activity in adult patients. Methods: A real‐world prospective multicentre cohort study was conducted across three NHS sites in England from August 2023 to June 2025. Adults with established EoE without oesophageal strictures underwent same‐day endoscopy and CS using the Endosign device. Histological activity was defined as ≥ 15 eosinophils per high‐power field or 0.3 mm 2 on endoscopic biopsy histology and CS respectively. Symptom burden was assessed using the Dysphagia Symptom Questionnaire, endoscopic severity using the EoE Endoscopic Reference Score and patient acceptability via structured questionnaire. Results: 136 patients (164 paired episodes) from three secondary care hospitals successfully swallowed CS with sufficient sampling; CS swallowing success rate was 92.7%. Median age was 45 years (IQR 34.8–56); 92/136 (67.6%) were male. CS demonstrated sensitivity 76.3%, specificity 89.5%, PPV 80.4%, NPV 87.0% and overall accuracy 84.8% (Cohen's κ = 0.67). AUC was 0.904 (95% CI 0.856–0.953). Patient acceptability recorded 96.7% found CS acceptable, 78.8% preferred it over endoscopy, and 90.8% would repeat the procedure. No complications occurred. Conclusions: CS is a safe, feasible, accurate and highly acceptable less‐invasive tool for monitoring EoE. Its implementation could improve care pathways, reducing the need for repeated endoscopic biopsies while maintaining diagnostic reliability, with potential to reduce service burden, carbon emissions and improve patient experience. Trial Registration: CoSiE: IRAS number: 314770; ClinicalTrials.gov identifier: NCT06501274; QuBiE: UK Clinical Trial registry identifier: ISRCTN14071734; Trial number: 10083253
- Open Access
- 25 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70286
Rethinking Barrett's Surveillance When Surveillance Is Most Questioned: Can Dedicated Lists Be Part of the Answer?
- 25 August 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (7) , e70286
Open AccessRethinking Barrett's Surveillance When Surveillance Is Most Questioned: Can Dedicated Lists Be Part of the Answer?